226 related articles for article (PubMed ID: 15901483)
1. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
Dalbem A; Silveira CV; Pedroso MF; Breda RV; Werne Baes CV; Bartmann AP; da Costa JC
Brain Res; 2005 Jun; 1047(2):148-58. PubMed ID: 15901483
[TBL] [Abstract][Full Text] [Related]
2. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Keene CD; Rodrigues CM; Eich T; Linehan-Stieers C; Abt A; Kren BT; Steer CJ; Low WC
Exp Neurol; 2001 Oct; 171(2):351-60. PubMed ID: 11573988
[TBL] [Abstract][Full Text] [Related]
3. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Pandey M; Borah A; Varghese M; Barman PK; Mohanakumar KP; Usha R
Neurochem Int; 2009 Nov; 55(6):431-7. PubMed ID: 19410615
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
[TBL] [Abstract][Full Text] [Related]
5. Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Colle D; Hartwig JM; Soares FA; Farina M
Brain Res Bull; 2012 Mar; 87(4-5):397-405. PubMed ID: 22245028
[TBL] [Abstract][Full Text] [Related]
6. Deficits in cortico-striatal synaptic plasticity and behavioral habituation in rats with portacaval anastomosis.
Sergeeva OA; Schulz D; Doreulee N; Ponomarenko AA; Selbach O; Borsch E; Kircheis G; Huston JP; Häussinger D; Haas HL
Neuroscience; 2005; 134(4):1091-8. PubMed ID: 16039790
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Tadros MG; Khalifa AE; Abdel-Naim AB; Arafa HM
Pharmacol Biochem Behav; 2005 Nov; 82(3):574-82. PubMed ID: 16337998
[TBL] [Abstract][Full Text] [Related]
8. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
Cirillo G; Maggio N; Bianco MR; Vollono C; Sellitti S; Papa M
Neurochem Int; 2010 Jan; 56(1):152-60. PubMed ID: 19799953
[TBL] [Abstract][Full Text] [Related]
9. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease.
Cummings DM; Milnerwood AJ; Dallérac GM; Vatsavayai SC; Hirst MC; Murphy KP
Brain Res Bull; 2007 Apr; 72(2-3):103-7. PubMed ID: 17352933
[TBL] [Abstract][Full Text] [Related]
10. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
El Massioui N; Ouary S; Chéruel F; Hantraye P; Brouillet E
Exp Neurol; 2001 Nov; 172(1):172-81. PubMed ID: 11681849
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
12. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
Lee ST; Park JE; Kim DH; Kim S; Im WS; Kang L; Jung SH; Kim MW; Chu K; Kim M
Brain Res; 2008 Feb; 1194():130-7. PubMed ID: 18166168
[TBL] [Abstract][Full Text] [Related]
14. Synaptic dysfunction in Parkinson's disease.
Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Kumar P; Kumar A
Behav Brain Res; 2010 Jan; 206(1):38-46. PubMed ID: 19716383
[TBL] [Abstract][Full Text] [Related]
16. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome.
Di Filippo M; Tozzi A; Ghiglieri V; Picconi B; Costa C; Cipriani S; Tantucci M; Belcastro V; Calabresi P
Biol Psychiatry; 2010 Apr; 67(7):666-71. PubMed ID: 19818432
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
18. [Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid].
Francis L; Cruz R; Antúnez I; Rosillo JC
Rev Neurol; 2000 Jun 1-15; 30(11):1016-21. PubMed ID: 10904945
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric spike-timing dependent plasticity of striatal nitric oxide-synthase interneurons.
Fino E; Paille V; Deniau JM; Venance L
Neuroscience; 2009 Jun; 160(4):744-54. PubMed ID: 19303912
[TBL] [Abstract][Full Text] [Related]
20. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease.
Duran-Vilaregut J; del Valle J; Manich G; Camins A; Pallàs M; Vilaplana J; Pelegrí C
Neuropathol Appl Neurobiol; 2011 Aug; 37(5):525-37. PubMed ID: 21175737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
